Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep 6;26(145):170046.
doi: 10.1183/16000617.0046-2017. Print 2017 Sep 30.

The lung in amyloidosis

Affiliations
Review

The lung in amyloidosis

Paolo Milani et al. Eur Respir Rev. .

Abstract

Amyloidosis is a disorder caused by misfolding of autologous protein and its extracellular deposition as fibrils, resulting in vital organ dysfunction and eventually death. Pulmonary amyloidosis may be localised or part of systemic amyloidosis.Pulmonary interstitial amyloidosis is symptomatic only if the amyloid deposits severely affect gas exchange alveolar structure, thus resulting in serious respiratory impairment. Localised parenchymal involvement may be present as nodular amyloidosis or as amyloid deposits associated with localised lymphomas. Finally, tracheobronchial amyloidosis, which is usually not associated with evident clonal proliferation, may result in airway stenosis.Because the treatment options for amyloidosis are dependent on the fibril protein type, the workup of all new cases should include accurate determination of the amyloid protein. Most cases are asymptomatic and need only a careful follow-up. Diffuse alveolar-septal amyloidosis is treated according to the underlying systemic amyloidosis. Nodular pulmonary amyloidosis is usually localised, conservative excision is usually curative and the long-term prognosis is excellent. Tracheobronchial amyloidosis is usually treated with bronchoscopic interventions or external beam radiation therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

FIGURE 1
FIGURE 1
Radiology assessment of pulmonary amyloidosis. a) Computed tomography (CT) scan of the chest of a patient with nodular pulmonary amyloidosis; b) diffuse interstitial pulmonary amyloidosis in a patient with light-chain amyloidosis: high-resolution CT of the chest shows diffuse subpleural septal thickening.

Comment in

References

    1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583–596. - PubMed
    1. Kyle R, Linos A, Beard C, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992; 79: 1817–1822. - PubMed
    1. Gertz M, Lacy M, Dispenzieri A. Amyloidosis. Hematol Oncol Clin North Am 1999; 13: 1211–1233. - PubMed
    1. Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification. International Society of Amyloidosis 2016 nomenclature guidelines. Amyloid 2016; 23: 209–213. - PubMed
    1. Riek R, Eisenberg DS. The activities of amyloids from a structural perspective. Nature 2016; 539: 227–235. - PubMed

MeSH terms

LinkOut - more resources